China’s cancer drug developer Ascentage secures $15m
Ascentage Pharma Group, a Shanghai-based cancer drug developer, has raised a RMB95 million ($15 million) Series A round of funding led by Oriza Seed and YuanMing Capital.
Domestic investors Efung Capital, Yuan Sheng Ventures and Grains Valley Capital also participated. The firm received RMB20 million in seed funding from Hong Kong-listed biotech firm 3SBio in 2010. Ascentage...
More on Greater China
Latest News
Asian GPs slow implementation of ESG policies - survey
Asia-based private equity firms are assigning more dedicated resources to environment, social, and governance (ESG) programmes, but policy changes have slowed in the past 12 months, in part due to concerns raised internally and by LPs, according to a...
Singapore fintech start-up LXA gets $10m seed round
New Enterprise Associates (NEA) has led a USD 10m seed round for Singapore’s LXA, a financial technology start-up launched by a former Asia senior executive at The Blackstone Group.
India's InCred announces $60m round, claims unicorn status
Indian non-bank lender InCred Financial Services said it has received INR 5bn (USD 60m) at a valuation of at least USD 1bn from unnamed investors including “a global private equity fund.”
Insight leads $50m round for Australia's Roller
Insight Partners has led a USD 50m round for Australia’s Roller, a venue management software provider specializing in family fun parks.